TY - JOUR
T1 - Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas
T2 - an indirect treatment comparison
AU - Schuster, Stephen J.
AU - Zhang, Jie
AU - Yang, Hongbo
AU - Agarwal, Abhijit
AU - Tang, Wenxi
AU - Martinez-Prieto, Marcela
AU - Bollu, Vamsi
AU - Kuzan, David
AU - Maziarz, Richard T.
AU - Kersten, Marie José
N1 - Funding Information:
Support for this study was provided by Novartis. Medical writing assistance was provided by Shelley Batts, Ph.D., an employee of Analysis Group, Inc. Support for this assistance was provided by Novartis.
Funding Information:
Jie Zhang, Marcela Martinez-Prieto, Vamsi Bollu, David Kuzan, and Abhijit Agarwal are employees of Novartis and own stock/options. Hongbo Yang and Wenxi Tang are employees of Analysis Group, Inc., which has received consulting fees from Novartis. Stephen Schuster has received research funding from Acerta, Abbvie, Adaptive Biotechnologies, Celgene/Juno, DTRM, Genentech/Roche, Gilead, Incyte, Merck, Novartis, Pharmacyclics, and TG Therapeutics, serves on steering committees for Celgene, Nordic Nanovector, Novartis, and Pfizer, has received honoraria from Abbvie, Acerta, Alimera Sciences, BeiGene, AstraZeneca, Celgene, Juno Therapeutics, Genentech/Roche, Loxo Oncology, Nordic Nanovector, Novartis, Pfizer, and Tessa Therapeutics, and has a patent for Combination Therapies of CAR and PD-1 Inhibitors (royalties to Novartis). Richard Maziarz is an advisor or consultant for AlloVir, Artiva, CRISPR Therapeutics, CytoDyn, Incyte, and Novartis; reports honoraria from Bristol-Myers Squibb/Celgene, Incyte, Intellia, and Kite; research support from BMS, Allovir, and Novartis; participation in a data and safety monitoring board for Athersys, Vor Pharma, and Novartis; and a patent with Athersys. Marie José Kersten has received research support from Kite/Gilead and Roche, and has received honoraria for speaking or advisory boards or travel support from Novartis, Kite/Gilead, BMS/Celgene, Roche, MSD, Amgen, Janssen/Cilag, and Miltenyi Biotech.
Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - This study compared overall survival (OS), progression-free survival (PFS), complete response rate (CRR), and overall response rate (ORR) of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in relapsed or refractory large B-cell lymphomas (r/r LBCL). Using matching-adjusted indirect comparison (MAIC), individual patient-level data from JULIET (tisa-cel) were weighted to match the patient population in TRANSCEND (liso-cel). The main analysis compared infused JULIET patients (N = 106) with the TRANSCEND efficacy-evaluable set (EES) (N = 256 [infused]). After adjustment, OS, PFS, and the CRR were comparable between tisa-cel and liso-cel EES patients. The estimated adjusted 2-year OS, 2-year PFS, ORR, and CRR were 45.6, 38.2, 62.9, and 47.7%, respectively, for tisa-cel vs. 43.8, 42.1, 72.7, and 53.1% for liso-cel. A scenario analysis compared JULIET patients to the TRANSCEND primary analysis set (PAS) (N = 133). ORR was significantly higher in the TRANSCEND PAS compared with matched JULIET patients, but no significant differences in CRR were observed.
AB - This study compared overall survival (OS), progression-free survival (PFS), complete response rate (CRR), and overall response rate (ORR) of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in relapsed or refractory large B-cell lymphomas (r/r LBCL). Using matching-adjusted indirect comparison (MAIC), individual patient-level data from JULIET (tisa-cel) were weighted to match the patient population in TRANSCEND (liso-cel). The main analysis compared infused JULIET patients (N = 106) with the TRANSCEND efficacy-evaluable set (EES) (N = 256 [infused]). After adjustment, OS, PFS, and the CRR were comparable between tisa-cel and liso-cel EES patients. The estimated adjusted 2-year OS, 2-year PFS, ORR, and CRR were 45.6, 38.2, 62.9, and 47.7%, respectively, for tisa-cel vs. 43.8, 42.1, 72.7, and 53.1% for liso-cel. A scenario analysis compared JULIET patients to the TRANSCEND primary analysis set (PAS) (N = 133). ORR was significantly higher in the TRANSCEND PAS compared with matched JULIET patients, but no significant differences in CRR were observed.
KW - Lisocabtagene maraleucel
KW - matching-adjusted indirect comparison
KW - relapsed or refractory large B-cell lymphoma
KW - tisagenlecleucel
UR - http://www.scopus.com/inward/record.url?scp=85122257799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122257799&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.2010069
DO - 10.1080/10428194.2021.2010069
M3 - Article
C2 - 34978255
AN - SCOPUS:85122257799
SN - 1042-8194
VL - 63
SP - 845
EP - 854
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -